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Background
Primary or transmitted HIV-1 drug resistance has caused
an alarm in developed countries. While certain HIV-1 sub-
type C polymorphisms in relation to consensus subtype B
sequences are known, there still exists a debate on the
validity of these mutations being associated with/mistaken
as, primary resistance. In this preliminary study, we have
determined polymorphisms in reverse transcriptase (RT)
and protease (PR) genes of HIV-1 subtype C from Mum-
bai, India.
Methods
The study was performed using plasma samples from 24
antiretroviral therapy-experienced and drug-naïve
patients employing a ‘home-brew’ semi-nested reverse-
transcriptase-PCR followed by sequencing and sequence
analysis. Analysis and interpretation of polymorphisms
and other drug-resistance mutations was carried out
using the Stanford HIV drug-resistance database. We
also analysed Surveillance Drug Resistance Mutations
(SDRMs) for PR gene.
Results
We determined polymorphisms at a mutational fre-
quency of 0.0670 ± 0.014 and 0.1337 ± 0.042, while
12.5% and 16.6% samples harboured drug-resistance
mutations in RT and PR genes respectively. Substitu-
tions greater than 50% were at positions D121, K122,
T165, K166, K173, D177, T200, Q207, R211 for RT and
L19, V82, M36, R41, L63, H69, L89, I93 for PR gene.
Additionally, PR gene SDRMs were observed in 15.0%
samples.
Conclusion
Our study re-iterates that polymorphisms in HIV-1 sub-
type C from India may also include a number of major
and minor/accessory mutations associated with resis-
tance. We recommend that HIV subtype-specific drug-
resistance databases be created to empower routine and
unambiguous surveillance of drug resistance prior to
initiating antiretroviral therapy, especially when includ-
ing Protease Inhibitors.
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